LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

Search

Relay Therapeutics Inc

Open

SectorHealthcare

3.66 4.27

Overview

Share price change

24h

Current

Min

3.51

Max

3.67

Key metrics

By Trading Economics

Income

6.7M

-70M

Sales

-7M

677K

Profit margin

-10,395.126

Employees

197

EBITDA

8M

-77M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+263.84% upside

Market Stats

By TradingEconomics

Market Cap

-21M

605M

Previous open

-0.61

Previous close

3.66

News Sentiment

By Acuity

50%

50%

172 / 372 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Relay Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 sie 2025, 22:51 UTC

Earnings

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H Rev $4.01B

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H Adj EPS $1.84

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H EPS $1.82

27 sie 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 sie 2025, 23:39 UTC

Earnings

Correction to Nvidia Earnings Article -- WSJ

27 sie 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 sie 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 sie 2025, 22:58 UTC

Earnings

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 sie 2025, 22:57 UTC

Earnings

South32 FY Free Cash Flow $192 Million

27 sie 2025, 22:56 UTC

Earnings

South32 FY Total Capital Expenditure $1.35 Billion

27 sie 2025, 22:56 UTC

Earnings

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 sie 2025, 22:55 UTC

Earnings

South32 Net Cash $123 Million at June 30

27 sie 2025, 22:54 UTC

Earnings

South32: Focused on Maintaining Strong Operating Momentum

27 sie 2025, 22:53 UTC

Earnings

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 sie 2025, 22:53 UTC

Earnings

South32 Extends Capital Management Program for 12 Months

27 sie 2025, 22:52 UTC

Earnings

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 sie 2025, 22:51 UTC

Earnings

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 sie 2025, 22:51 UTC

Earnings

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 sie 2025, 22:50 UTC

Earnings

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 sie 2025, 22:50 UTC

Earnings

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 sie 2025, 22:45 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 sie 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 sie 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 sie 2025, 22:43 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 sie 2025, 22:43 UTC

Earnings

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 sie 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 sie 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 sie 2025, 22:40 UTC

Earnings

Sandfire Resources Net Debt $123 Million at June 30

27 sie 2025, 22:40 UTC

Earnings

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Comparison

Price change

Relay Therapeutics Inc Forecast

Price Target

By TipRanks

263.84% upside

12 Months Forecast

Average 12.88 USD  263.84%

High 19 USD

Low 4 USD

Based on 10 Wall Street analysts offering 12 month price targets forRelay Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

8

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

2.88 / 3.285Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

172 / 372 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.